The Apex of Therapeutics
Company Introduction
Therapex is committed to growth and evolution
Therapex’s every moment of breath
  • 04
    Changing the corporate name to Therapex
  • 04
    Completing the spinoff of Organoid Division
  • 02
    Joint research agreement with Elgen Therapeutics on developing PROTAC agents
    엘젠테라퓨틱스와 PROTAC 공동연구 협약
  • 09
    Embarking on build-up of new drug R&D pipeline
  • 08
    Moving the headquarter and R&D cancer to Songpa Area with expanded capacity
  • 03
    Appointing Dr. Koo Lee as CEO
  • 10
    In-licensing agreement with BiSiChem on anti-cancer drug candidate, IBC-1131
  • 09
    Joint research agreement with Korea Research Institute of Chemical Technology on developing new anti-cancer drugs
  • 08
    Joint research agreement with Yonsei University Severance Biomedical Science Institute on developing new drugs for lung cancer patients
  • 07
    Founded Interpark Bioconvergence Corp.